Loading…
Bionano Genomics, Inc. is projected to decline to $1.17 by 2027, a -2% move from its current price of $1.20. BNGO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.17 | $1.20 | $1.23 | +0.02% |
| Jul 14 | $1.16 | $1.20 | $1.24 | +0.04% |
| Jul 15 | $1.16 | $1.20 | $1.25 | +0.06% |
| Jul 16 | $1.15 | $1.20 | $1.25 | +0.07% |
| Jul 17 | $1.14 | $1.20 | $1.26 | +0.09% |
| Jul 18 | $1.14 | $1.20 | $1.27 | +0.11% |
| Jul 19 | $1.13 | $1.20 | $1.27 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.13 | $1.20 | $1.27 | +0.13% |
| Week 2 | $1.11 | $1.20 | $1.31 | +0.26% |
| Week 3 | $1.09 | $1.20 | $1.33 | +0.39% |
| Week 4 | $1.07 | $1.21 | $1.36 | +0.52% |
| Week 5 | $1.06 | $1.21 | $1.38 | +0.66% |
| Week 6 | $1.05 | $1.21 | $1.40 | +0.79% |
| Week 7 | $1.04 | $1.21 | $1.41 | +0.92% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome testing services; NextStepDx PLUS, an exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing.
Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
BNGO is a healthcare company focused on genome analysis solutions, with a global footprint spanning multiple regions and a suite of software, instruments, chips, kits, and services aimed at identifying genetic variation and function. Its current liquidity and market presence are modest, reflecting a small-cap profile with a market capitalization of $13.2M and a rank of 5041.
The stock’s near-term forecast shows a neutral trajectory for 2026, with min $1.09, avg $1.15, max $1.45 and a 0% ROI; sentiment is NEUTRAL. Looking further, the multi-year forecast transitions to a bullish stance from 2031 onward, with rising averages and meaningful ROIs in later years (2031 avg $1.44, ROI 25%; 2032 avg $1.48, ROI 29%; 2033 avg $1.55, ROI 34.6%; 2040 avg $2.13, ROI 85.5%; 2050 avg $3.29, ROI 185.8%). The 2030 forecast sits at an avg of $1.23 with a 6.6% ROI, signaling gradual upside into the next decade.
Overall, the price outlook shows potential upside over the longer term, albeit from a very low base and with substantial uncertainty and volatility inherent in the small-cap space.
A major floor 14.4% below — a decisive break under it would weaken the trend.
The nearest floor, 6.7% below — buyers have tended to step in here.
The nearest ceiling, 8.3% above — a clean break opens room to run.
A major ceiling 21.7% above — clearing it would confirm fresh momentum.
Key BNGO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BNGO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.15 | Buy | $1.16 | Buy |
| MA 10 | $1.15 | Buy | $1.16 | Buy |
| MA 20 | $1.15 | Buy | $1.16 | Buy |
| MA 50 | $1.19 | Buy | $1.18 | Buy |
| MA 100 | $1.18 | Buy | $1.28 | Sell |
| MA 200 | $1.41 | Sell | $2.78 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.66 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 207.79 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 4.35 | Buy |
| Bollinger %B (20,2) | 1.11 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.21 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 64.15 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 1.15 | Buy |
| ADX (14) | 11.88 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is bearish at present. RSI(14) stands at 40, reflecting modest negative momentum, while the 50-day simple moving average sits at $1.22 and the 200-day simple moving average at $1.58, indicating a softer near-term trend compared with longer-term averages.
Price currently sits near the $1.15 support and faces resistance near $1.33. The 30-day trading range runs from a low of $0.9858 to a high of $1.34, framing the near-term volatility and potential breakout levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.09 | $1.20 | $1.52 | 0% | Neutral | |
| $0.9493 | $1.17 | $1.52 | -2% | Neutral | |
| $1.00 | $1.27 | $1.69 | +6% | Neutral | |
| $0.9743 | $1.25 | $1.71 | +4% | Neutral | |
| $1.02 | $1.33 | $1.86 | +11% | Neutral | |
| $1.19 | $1.58 | $2.25 | +32% | Bullish | |
| $1.20 | $1.61 | $2.33 | +34% | Bullish | |
| $1.24 | $1.68 | $2.47 | +40% | Bullish | |
| $1.25 | $1.72 | $2.56 | +44% | Bullish | |
| $1.16 | $1.61 | $2.43 | +35% | Bullish | |
| $1.64 | $2.40 | $3.82 | +100% | Bullish | |
| $2.37 | $3.78 | $6.48 | +215% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.09 | $1.20 | $1.46 | +0.00% |
| August 2026 | $1.05 | $1.23 | $1.48 | +2.50% |
| September 2026 | $1.03 | $1.22 | $1.48 | -0.76% |
| October 2026 | $1.05 | $1.25 | $1.53 | +2.27% |
| November 2026 | $1.06 | $1.26 | $1.55 | +1.11% |
| December 2026 | $1.03 | $1.23 | $1.52 | -2.45% |
Click any year to see its month-by-month BNGO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BNGO is projected to trade between $1.09 and $1.52, averaging $1.20 — a potential gain of 0% from today's $1.20. A consolidation phase looks the most probable path here.
Bionano Genomics, Inc.'s 2027 outlook centres on $1.17, within a $0.9493 to $1.52 range. That is -2% versus the projected 2026 average. That marks a -2% change versus current levels. Price action looks broadly range-bound.
By 2028, BNGO could reach as high as $1.69, with a base case around $1.27 and support toward $1.00 — roughly +6% from $1.20. A consolidation phase looks the most probable path here.
Expect BNGO to range from $0.9743 to $1.71 through 2029. The $1.25 average target implies a +4% move from current prices. That is -1% versus the projected 2028 average. Price action looks broadly range-bound.
The BNGO price prediction for 2030 points to an average of $1.33 (low $1.02, high $1.86) — a potential gain of +11% on today's $1.20. A consolidation phase looks the most probable path here.
In 2031, BNGO is projected to trade between $1.19 and $2.25, averaging $1.58 — a potential gain of +32% from today's $1.20. That is up +19% on the projected 2030 average. Momentum favours further upside here.
Bionano Genomics, Inc.'s 2032 outlook centres on $1.61, within a $1.20 to $2.33 range. That is up +2% on the projected 2031 average. That marks a +34% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BNGO could reach as high as $2.47, with a base case around $1.68 and support toward $1.24 — roughly +40% from $1.20. Momentum favours further upside here.
Expect BNGO to range from $1.25 to $2.56 through 2034. The $1.72 average target implies a +44% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The BNGO price prediction for 2035 points to an average of $1.61 (low $1.16, high $2.43) — a potential gain of +35% on today's $1.20. Momentum favours further upside here.
In 2040, BNGO is projected to trade between $1.64 and $3.82, averaging $2.40 — a potential gain of +100% from today's $1.20. That is up +49% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Bionano Genomics, Inc.'s 2050 outlook centres on $3.78, within a $2.37 to $6.48 range. That is up +57% on the projected 2040 average. That marks a +215% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BNGO today (≈ 833.333333 BNGO) could be worth
$3,148.36
+$2,148.36 (+215%) by 2050 · US Dollar
Based on the average projected BNGO price of $3.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BNGOwould be worth at today's price.
$1,000 invested in BNGO on Jul 10, 2025 (≈ 294.117639 BNGO) would be worth
$352.94
-$647.06 (-64.7%) today · 0.35× · US Dollar
Based on a BNGO entry price of $3.4 vs. today's $1.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.15 | $1,043.48 | +4.3% |
| 1 month ago | $1.16 | $1,034.48 | +3.4% |
| 3 months ago | $1.13 | $1,061.95 | +6.2% |
| 6 months ago | $1.59 | $754.72 | -24.5% |
| 1 year ago | $3.4 | $352.94 | -64.7% |
| All time (5.0y) ago | $3,654 | $0.33 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BNGO forecast.
Our base-case forecast reaches $2.40 around 2040.
Implied market cap at $2.40: $27.54M
The multi-year forecast shows a gradual, but meaningful, upside path after 2026. In 2030 the average price is projected at $1.23 with a 6.6% ROI, while the 2031–2033 window turns more bullish: 2031 avg $1.44 (ROI 25%), 2032 avg $1.48 (ROI 29%), 2033 avg $1.55 (ROI 34.6%). By 2040 the average climbs to $2.13 with an 85.5% ROI, and by 2050 it reaches an average of $3.29 with a 185.8% ROI.
The sentiment shifts to BULLISH starting in 2031, continuing through 2040 and 2050.
These projections imply a path of gradual upside from a low base, with notable acceleration in the 2030s and into 2050. Investors should note that these are estimates, not guarantees, and are subject to substantial uncertainty and market volatility inherent in micro-cap equities.
Tap a question to reveal the answer.
2030 avg $1.23, min $0.9308, max $1.73, ROI 6.6%, sentiment NEUTRAL.
In 2026 the forecast shows avg $1.15 with ROI 0% and NEUTRAL sentiment. From 2031 onward the forecast becomes bullish, with rising averages and ROIs (2031 avg $1.44; 2032 avg $1.48; 2040 avg $2.13; 2050 avg $3.29) and bullish sentiment.
The 2030 max is $1.73, but the 2031–2033 max values rise to $2.07, $2.17, and $2.30 respectively; by 2040 the max is $3.44 and by 2050 the max is $5.75, indicating potential to exceed $2 in later years.
Current price is $1.15 and market cap is $13.2M; the rank is 5041.
Bearish sentiment with RSI(14) at 40; SMA50 at $1.22; SMA200 at $1.58; support at $1.15 and resistance at $1.33; 30-day range from $0.9858 to $1.34.
Bionano Genomics, Inc. Community Discussion
0Share your Bionano Genomics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.